Moderna's Cancer Vaccine Works. Now Comes the Invoice Nobody Has Written.

Moderna has cleared its biggest clinical hurdle in oncology. Whether that translates into a business is a separate question — and it is the one now dominating the conversation around the stock.

The company and Merck published Phase 3 results from the INTerpath-001 trial on Thursday, ahead of schedule after an embargo break. The formal presentation was set for the ESMO congress in Madrid. That early release shifted attention quickly from the headline win to its precise dimensions — and to what the market had already priced in.

What the trial actually showed

The study enrolled 1,137 patients whose high-risk melanoma had been completely surgically removed. Adding intismeran autogene to Keytruda cut the relative risk of recurrence or death by 42% versus Keytruda alone. The reduction in the risk of distant metastasis or death came in at 38%.

At two years, 82.2% of patients on the combination remained recurrence-free, compared with 70.0% in the control arm. A prespecified analysis running from the end of the roughly six-month vaccination period showed a stronger effect, with recurrence or death risk down 58%.

Those figures establish genuine clinical benefit, not a promise about a technology. They also carry firm boundaries. The trial tested treatment after surgery; it does not demonstrate benefit in active, inoperable or metastatic melanoma. And this is a therapeutic vaccine, not a preventive one. Overall survival data remain immature — fewer relapses matter, but how long the advantage holds and whether it extends survival will only emerge with longer follow-up.

Should investors sell immediately? Or is it worth buying Moderna?

A 573% run sets a high bar

Moderna shares are up 573% year to date, even after the recent pullback. That gain goes a long way toward explaining why solid data did not produce a rally: investors were not grading the progress alone, but the distance between it and what the share price already assumed. The Wall Street Journal framed the situation accordingly — the first major test has been passed, while the valuation had already anticipated far-reaching success.

Analysts drew different conclusions from the same release. Citi's Geoff Meacham reaffirmed a sell rating and an $80.00 price target on Thursday, questioning whether the treatment benefit justifies the work of collecting individual tumor material and manufacturing a bespoke therapy. He also pointed to expectations for broader oncology success baked into the stock. Bernstein, by contrast, maintained a neutral rating and read the share-price decline as profit-taking after a long-awaited announcement.

RBC's Trung Huynh sees approval as likely but commercial success as uncertain, citing the pending comparison against a cheaper standard of care. That is not a challenge to the medical evidence. It is the question of how much added benefit health systems will pay for, and at what price.

The manufacturing problem is the business problem

Personalized cancer medicine carries its economics inside its science. Each treatment is tailored to an individual tumor — that is the therapeutic premise, and simultaneously a challenge for production, cost control and access. Manufacturing takes roughly six weeks per patient. Oxford professor Lennard Lee has warned of a complex and potentially expensive process. No price has been disclosed, leaving affordability an open question.

The path to market remains conditional as well. Moderna is preparing a US regulatory filing, according to CEO Stéphane Bancel, and a launch could conceivably come in 2027 on company statements. Approval is not assured.

Moderna has scheduled an oncology investor event alongside the ESMO presentation, giving it a stage to lay out its commercial case. The next confirmed financial date is November 6, 2026, when third-quarter 2026 results are due — a reminder that the balance sheet, not just the data readout, will shape the verdict.

The clinical result gives Moderna a foundation. Turning it into a reliably manufacturable and financeable product is a different test, and one that efficacy alone will not settle.

Ad

Moderna Stock: New Analysis - 24 October

Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Moderna analysis...